Magnetic Resonance - Technology Information Portal Welcome to MRI Technology
Info
  Sheets

Out-
      side
 



 
 'Eovist' 
SEARCH FOR    
 
  2 3 5 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Result : Searchterm 'Eovist' found in 1 term [] and 4 definitions []
1 - 5 (of 5)     
Result Pages : [1]
Eovist®InfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.
 
Eovist® (other brand name Primovist™) is a organ specific MRI contrast agent for the imaging, detection and characterization of liver conditions, including liver tumors, cysts, as well as other malignant and benign lesions. It is a water-soluble ethoxybenzyl derivative of Gd-DTPA. This compound is taken up by the hepatocytes (approximately 30% of the dose goes to the hepatocytes) and is equally excreted renal and biliary in humans. Excretion of Gd-EOB-DTPA in the bile may also permit visualization of both the gall bladder and the bile ducts.
Eovist® brightens the signal of T1 weighted MR images immediately after contrast administration. Dynamic and accumulation phase imaging can also be performed after bolus injection of Eovist®. The hepatocytes uptake will increase the signal intensity of normal liver parenchyma at 10 to 20 minutes after injection. This results in improved lesion-to-liver contrast because malignant tumors (metastases, the majority of hepatocellular carcinomas) do not contain either hepatocytes or their functioning is hampered.

WARNING: Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or chronic severe renal insufficiency (glomerular filtration rate less than 30 mL/min/1.73m2), or acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period.

See also Drug Development and Approval Process USA, Contrast Medium, Hepatobiliary Contrast Agents, Tumor Specific Agents and Molecular Imaging.
Drug Information and Specification
NAME OF COMPOUND
Gadoxetic acid disodium, Gd-EOB-DTPA
CENTRAL MOIETY
Gd2+
CONTRAST EFFECT
T1, Predominantly positive enhancement
Short T1-relaxation time
PHARMACOKINETIC
50% hepatobiliary, 50% renal excretion
884 mosm/kgH2O
CONCENTRATION
0.25 mol/L
DOSAGE
12,5 - 25 µmol/kg
PREPARATION
Finished product
INDICATION
Liver lesions
DEVELOPMENT STAGE
For sale
DISTRIBUTOR
See below
PRESENTATION
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE
NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!
spacer
 
• Share the entry 'Eovist®':  Facebook  Twitter  LinkedIn  
 
Further Reading:
  Basics:
HIGHLIGHTS OF PRESCRIBING INFORMATION
2008   by berlex.bayerhealthcare.com    
MRI Resources 
Hospitals - Collections - Portals - Process Analysis - MRCP - Societies
 
Primovist™InfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
Primovist™ (U.S brand name Eovist®) is a highly specific MRI contrast agent for the imaging, detection and characterization of liver conditions, including liver tumors, cysts, as well as other malignant and benign lesions. It is a water-soluble ethoxybenzyl derivative of Gd-DTPA. This compound is taken up by the hepatocytes (approximately 30% of the dose goes to the hepatocytes) and is equally excreted renal and biliary in humans.
Primovist™ brightens the signal of T1 weighted MR images immediately after contrast administration. Dynamic scanning and imaging of the accumulation phase (best after 20 min.) can also be performed after bolus injection of Primovistâ„¢. The hepatocytes uptake will increase the signal intensity of normal liver parenchyma. This results in improved lesion-to-liver contrast because malignant tumors (metastases, the majority of hepatocellular carcinomas) do not contain either hepatocytes or their functioning is hampered.

WARNING: Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or chronic severe renal insufficiency (glomerular filtration rate less than 30 mL/min/1.73m2), or acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period.
Drug Information and Specification
NAME OF COMPOUND
Gadoxetic acid disodium, Gd-EOB-DTPA
CENTRAL MOIETY
Gd2+
CONTRAST EFFECT
T1, Predominantly positive enhancement
Short T1-relaxation time
PHARMACOKINETIC
50% hepatobiliary, 50% renal excretion
884 mosm/kgH2O
CONCENTRATION
0.25 mol/L
DOSAGE
12,5 - 25 µmol/kg
PREPARATION
Finished product
INDICATION
Liver lesions
DEVELOPMENT STAGE
for sale
DISTRIBUTOR
See below
PRESENTATION
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE
NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!
Distribution Information
TERRITORY
TRADE NAME
DEVELOPMENT
STAGE
DISTRIBUTOR
EU
Primovist™
for sale
spacer

• View the DATABASE results for 'Primovist™' (7).Open this link in a new window

 
Further Reading:
  Basics:
New MRI liver contrast agent Primovist® approved in EU
Thursday, 30 September 2004   by www.secinfo.com    
New MRI Liver Contrast Medium
Wednesday, 13 October 2004   by www.hospimedica.com    
Important Drug Warning for Gadolinium-Based Contrast Agents
Wednesday, 12 September 2007   by www.ismrm.org    
MAGNETIC RESONANCE IMAGING OF FOCAL LIVER LESIONS(.pdf)
2002
  News & More:
Comparison of liver scintigraphy and the liver-spleen contrast in Gd-EOB-DTPA-enhanced MRI on liver function tests
Thursday, 18 November 2021   by www.nature.com    
EMA's final opinion confirms restrictions on use of linear gadolinium agents in body scans
Friday, 21 July 2017   by www.ema.europa.eu    
FDA Drug Safety Communication: FDA warns that gadolinium-based contrast agents (GBCAs) are retained in the body; requires new class warnings
Tuesday, 19 December 2017   by www.fda.gov    
Gadolinium-containing contrast agents: removal of Omniscan and iv Magnevist, restrictions to the use of other linear agents
Friday, 5 January 2018   by www.gov.uk    
MRI Resources 
MRI Training Courses - Pathology - Movies - Breast Implant - Contrast Enhanced MRI - Musculoskeletal and Joint MRI
 
Bayer Schering Pharma AGMRI Resource Directory:
 - Manufacturers -
 
www.bayerscheringpharma.de/scripts/pages/en/index.php The Germany-based pharmaceutical company is the result of the take-over of Schering AG by Bayer AG in 2006. The Bayer Schering Pharma AG is part of the Bayer HealthCare AG, which represents the pharmaceutical part of the Bayer Group. Activities of the Bayer Schering Pharma AG are Diagnostic Imaging, Hematology and Cardiology, Oncology, Primary Care, Specialized Therapeutics and Women's Healthcare. The diagnostic imaging part's contrast agents for MRI, x-ray and computed tomography are 'world-market leaders'.

MRI Contrast Agents:
Contact Information
MAIL
Bayer Schering Pharma AG
51368 Leverkusen
GERMANY
PHONE
+49-30-46-81-2431
FAX
+49-30-46-81-8195
spacer

• View the DATABASE results for 'Bayer Schering Pharma AG' (22).Open this link in a new window


• View the NEWS results for 'Bayer Schering Pharma AG' (25).Open this link in a new window.
 
Further Reading:
  News & More:
Drastic market changes with MRI contrast media and PET radiopharmaceuticals emerging as most promising segments
Thursday, 21 October 2004   by www.news-medical.net    
Epix Pharmaceuticals to shut down
Tuesday, 21 July 2009   by boston.bizjournals.com    
Gadoxetic AcidInfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.
 
Short name: Gd-EOB-DTPA, generic name: Gadoxetic acid, chemical compound: Gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid
Primovist™ (formerly Eovist®) is a nonionic water-soluble liver tissue-specific MRI contrast agent with positive enhancement. The agent allows detection and differentiation of hepatic tumors due to specific uptake by healthy liver tissue, but not by tumors in the affected organ. Gd-EOB-DTPA has hepatocyte-specific properties, but provides earlier perfusion information acquired within first ten minutes. Hepatocyte uptake generally occurs beyond 10 minutes.
spacer

• View the DATABASE results for 'Gadoxetic Acid' (6).Open this link in a new window

 
Further Reading:
  Basics:
Added Value of Gadoxetic Acid-enhanced Liver Magnetic Resonance Imaging for Diagnosis of Small (10-19 mm) or Atypical Hepatic Nodules at Contrast-enhanced Computed Tomography: A Prospective Study
Tuesday, 7 February 2017   by www.clinicaltrials.gov    
  News & More:
Pilot study of gadoxetate disodium-enhanced mri for localized and metastatic prostate cancers
Thursday, 11 March 2021   by www.docwirenews.com    
New MRI Liver Contrast Medium
Wednesday, 13 October 2004   by www.hospimedica.com    
MRI Resources 
Knee MRI - Sequences - Cochlear Implant - Databases - Mass Spectrometry - Devices
 
Liver ImagingForum -
related threadsMRI Resource Directory:
 - Liver Imaging -
 
Liver imaging can be performed with sonography, computed tomography (CT) and magnetic resonance imaging (MRI). Ultrasound is, caused by the easy access, still the first-line imaging method of choice; CT and MRI are applied whenever ultrasound imaging yields vague results. Indications are the characterization of metastases and primary liver tumors e.g., benign lesions such as focal nodular hyperplasia (FNH), adenoma, hemangioma and malignant lesions (cancer) such as hepatocellular carcinomas (HCC). The decision, which medical imaging modality is more suitable, MRI or CT, is dependent on the different factors. CT is less costly and more widely available; modern multislice scanners provide high spatial resolution and short scan times but has the disadvantage of radiation exposure.
With the introduction of high performance MR systems and advanced sequences the image quality of MRI for the liver has gained substantially. Fast spin echo or single shot techniques, often combined with fat suppression, are the most common T2 weighted sequences used in liver MRI procedures. Spoiled gradient echo sequences are used as ideal T1 weighted sequences for evaluating of the liver. The repetition time (TR) can be sufficiently long to acquire enough sections covering the entire liver in one pass, and to provide good signal to noise. The TE should be the shortest in phase echo time (TE), which provides strong T1 weighting, minimizes magnetic susceptibility effects, and permits acquisition within one breath hold to cover the whole liver. A flip angle of 80° provides good T1 weighting and less of power deposition and tissue saturation than a larger flip angle that would provide comparable T1 weighting.
Liver MRI is very dependent on the administration of contrast agents, especially when detection and characterization of focal lesions are the issues. Liver MRI combined with MRCP is useful to evaluate patients with hepatic and biliary disease.
Gadolinium chelates are typical non-specific extracellular agents diffusing rapidly to the extravascular space of tissues being cleared by glomerular filtration at the kidney. These characteristics are somewhat problematic when a large organ with a huge interstitial space like the liver is imaged. These agents provide a small temporal imaging window (seconds), after which they begin to diffuse to the interstitial space not only of healthy liver cells but also of lesions, reducing the contrast gradient necessary for easy lesion detection. Dynamic MRI with multiple phases after i.v. contrast media (Gd chelates), with arterial, portal and late phase images (similar to CT) provides additional information.
An additional advantage of MRI is the availability of liver-specific contrast agents (see also Hepatobiliary Contrast Agents). Gd-EOB-DTPA (gadoxetate disodium, Gadolinium ethoxybenzyl dimeglumine, EOVIST Injection, brand name in other countries is Primovist) is a gadolinium-based MRI contrast agent approved by the FDA for the detection and characterization of known or suspected focal liver lesions.
Gd-EOB-DTPA provides dynamic phases after intravenous injection, similarly to non-specific gadolinium chelates, and distributes into the hepatocytes and bile ducts during the hepatobiliary phase. It has up to 50% hepatobiliary excretion in the normal liver.
Since ferumoxides are not eliminated by the kidney, they possess long plasmatic half-lives, allowing circulation for several minutes in the vascular space. The uptake process is dependent on the total size of the particle being quicker for larger particles with a size of the range of 150 nm (called superparamagnetic iron oxide). The smaller ones, possessing a total particle size in the order of 30 nm, are called ultrasmall superparamagnetic iron oxide particles and they suffer a slower uptake by RES cells. Intracellular contrast agents used in liver MRI are primarily targeted to the normal liver parenchyma and not to pathological cells. Currently, iron oxide based MRI contrast agents are not marketed.
Beyond contrast enhanced MRI, the detection of fatty liver disease and iron overload has clinical significance due to the potential for evolution into cirrhosis and hepatocellular carcinoma. Imaging-based liver fat quantification (see also Dixon) provides noninvasively information about fat metabolism; chemical shift imaging or T2*-weighted imaging allow the quantification of hepatic iron concentration.

See also Abdominal Imaging, Primovistâ„¢, Liver Acquisition with Volume Acquisition (LAVA), T1W High Resolution Isotropic Volume Examination (THRIVE) and Bolus Injection.

For Ultrasound Imaging (USI) see Liver Sonography at Medical-Ultrasound-Imaging.com.
 
Images, Movies, Sliders:
 Anatomic Imaging of the Liver  Open this link in a new window
      

 MRI Liver T2 TSE  Open this link in a new window
    
 
Radiology-tip.comradAbdomen CT,  Biliary Contrast Agents
spacer
Medical-Ultrasound-Imaging.comLiver Sonography,  Vascular Ultrasound Contrast Agents
spacer

• View the DATABASE results for 'Liver Imaging' (13).Open this link in a new window


• View the NEWS results for 'Liver Imaging' (10).Open this link in a new window.
 
Further Reading:
  Basics:
Comparison of liver scintigraphy and the liver-spleen contrast in Gd-EOB-DTPA-enhanced MRI on liver function tests
Thursday, 18 November 2021   by www.nature.com    
Liver Imaging Today
Friday, 1 February 2013   by www.healthcare.siemens.it    
Elastography: A Useful Method in Depicting Liver Hardness
Thursday, 15 April 2010   by www.sciencedaily.com    
Iron overload: accuracy of in-phase and out-of-phase MRI as a quick method to evaluate liver iron load in haematological malignancies and chronic liver disease
Friday, 1 June 2012   by www.ncbi.nlm.nih.gov    
  News & More:
Utility and impact of magnetic resonance elastography in the clinical course and management of chronic liver disease
Saturday, 20 January 2024   by www.nature.com    
Even early forms of liver disease affect heart health, Cedars-Sinai study finds
Thursday, 8 December 2022   by www.eurekalert.org    
For monitoring purposes, AI-aided MRI does what liver biopsy does with less risk, lower cost
Wednesday, 28 September 2022   by radiologybusiness.com    
Perspectum: High Liver Fat (Hepatic Steatosis) Linked to Increased Risk of Hospitalization in COVID-19 Patients With Obesity
Monday, 29 March 2021   by www.businesswire.com    
EMA's final opinion confirms restrictions on use of linear gadolinium agents in body scans
Friday, 21 July 2017   by www.ema.europa.eu    
T2-Weighted Liver MRI Using the MultiVane Technique at 3T: Comparison with Conventional T2-Weighted MRI
Friday, 16 October 2015   by www.ncbi.nlm.nih.gov    
EORTC study aims to qualify ADC as predictive imaging biomarker in preoperative regimens
Monday, 4 January 2016   by www.eurekalert.org    
MRI effectively measures hemochromatosis iron burden
Saturday, 3 October 2015   by medicalxpress.com    
Total body iron balance: Liver MRI better than biopsy
Sunday, 15 March 2015   by www.eurekalert.org    
MRI Resources 
Calculation - Spectroscopy - RIS - Breast MRI - Chemistry - Pediatric and Fetal MRI
 
     1 - 5 (of 5)     
Result Pages : [1]
 Random Page
 
Share This Page
FacebookTwitterLinkedIn

MR-TIP    
Community   
User
Pass
Forgot your UserID/Password ?    



MRI is trending to low field magnets :
reduced costs will lead to this change 
AI will close the gap to high field 
only in remote areas 
is only temporary 
never 

Look
      Ups





MR-TIP.com uses cookies! By browsing MR-TIP.com, you agree to our use of cookies.

Magnetic Resonance - Technology Information Portal
Member of SoftWays' Medical Imaging Group - MR-TIP • Radiology-TIP • Medical-Ultrasound-Imaging • 
Copyright © 2003 - 2024 SoftWays. All rights reserved. [ 28 March 2024]
Terms of Use | Privacy Policy | Advertising
 [last update: 2024-02-26 03:41:00]